Diane 35 is a prescription-only oral medication marketed for women’s health. Each pill contains cyproterone acetate 2 mg and ethinylestradiol 0.035 mg, a fixed-dose combination formulated as a small round tablet. In Hong Kong the product is regulated by the Department of Health under the Pharmacy and Poisons Ordinance and is only dispensed with a qualified prescriber’s order. The combination is classified as a combined oral contraceptive (COC) with added anti-androgenic activity, which distinguishes it from standard COCs that contain only a progestin and an estrogen.
Diane 35 exerts its therapeutic effect through two complementary mechanisms:
Together, these actions lower androgen-driven skin changes (such as acne and excess facial hair) and provide reliable contraception by inhibiting ovulation. Onset of hormonal effects occurs within a few days, while full steady-state suppression is typically achieved after two cycles of consistent daily intake. The tablet’s bioavailability is high when taken with food, and it is metabolised primarily in the liver via the cytochrome P450 system before renal excretion.
In Hong Kong, Diane 35 is approved for the following indications:
The medication is indicated for adult women of reproductive age who have no contraindications to combined estrogen-progestin therapy. It is not intended for use in adolescents under 18 years unless a specialist determines a clear medical need.
Before initiating therapy, clinicians evaluate each of these factors to ensure safety.
These effects are usually mild and tend to improve after the first few cycles.
The product carries a black-box warning for venous and arterial thromboembolism, consistent with regulatory guidance for combined estrogen-progestin preparations.
Because interaction data for Diane 35 are limited, patients should disclose all prescription medicines, over-the-counter products, herbal supplements, and vitamins to their prescriber.
Note: All dosing instructions must be confirmed and personalised by a qualified healthcare professional.
Regular follow-up appointments (typically every 12 months) enable early detection of adverse effects and ensure continued appropriateness of therapy.
This article provides educational information about Diane 35 and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes. While Diane 35 is frequently prescribed for severe acne and hirsutism, it also functions as an effective combined oral contraceptive when taken according to the 21-day regimen.
Cyproterone acetate has a stronger anti-androgenic effect than many progestins used in standard COCs, which can provide additional benefit for women with androgen-related skin conditions.
Travel does not alter the medication’s pharmacology. However, ensure you carry enough tablets for the entire trip, keep them in their original packaging, and be aware of any country-specific regulations regarding hormonal contraceptives.
Breakthrough bleeding can be a normal adjustment when starting or switching hormonal therapy. If bleeding persists beyond two cycles or is heavy, contact your prescriber for evaluation.
Herbal products such as St. John’s wort can increase hormone metabolism, potentially reducing contraceptive effectiveness. Always disclose supplement use to your healthcare provider.
Combined oral contraceptives may slightly impair glucose tolerance. Diabetic women should monitor blood glucose more closely after initiating therapy and discuss any changes with their physician.
The estrogen dose (0.035 mg ethinylestradiol) is similar to many COCs, but the anti-androgenic progestin may contribute to a modestly increased clotting risk. Individual risk factors, such as smoking or a personal history of thrombosis, play a larger role.
Baseline assessments often include blood pressure measurement, liver function tests, and a review of personal and family clotting history. Specific laboratory tests are ordered based on individual risk factors.
A direct switch is generally acceptable if the previous pill’s regimen has been completed and the new tablet is started the following day. Your prescriber will confirm the appropriate timing based on your cycle.
Missing two or more consecutive pills significantly reduces contraceptive coverage. You should take the most recent missed tablet as soon as possible, discard any remaining missed tablets, and use a reliable backup method (e.g., condoms) for the next 7 days.
